The 2022 Abbott Formula Recall - What Happened, Why It Mattered, and What's Changed Since — The Infant Formula Atlas

By María López Botín · Mother of 2, researching infant formula and infant nutrition since 2018

On February 17, 2022, Abbott Nutrition voluntarily recalled Similac, Alimentum, and EleCare powdered infant formulas produced at its Sturgis, Michigan plant after four infant illnesses and at least two deaths linked to Cronobacter sakazakii and Salmonella Newport infections. The plant shut down within days. The cascading supply shortage that followed became the most severe US infant formula crisis in modern history, with store shelves empty for months, parents driving across state lines to find product, and the federal government invoking the Defense Production Act and Operation Fly Formula to import emergency supply from Europe and Australia. Four years later, the incident has reshaped the US formula market, accelerated FDA enforcement discretion for European brands, and produced specific regulatory and commercial changes worth understanding.

The February 2022 Abbott recall originated at the Sturgis, Michigan plant after FDA inspection found Cronobacter sakazakii and sanitation failures. Four infant illnesses and at least two deaths were linked to the facility. The plant closed for months. US formula supply dropped roughly 40-50% at peak shortage (May-June 2022). Federal response included Operation Fly Formula, Defense Production Act invocation, and FDA enforcement discretion allowing European and Australian brand imports. Market share shifted significantly toward Bobbie, Kendamil, Reckitt/Mead Johnson, and European imports. The Sturgis plant reopened in July 2022 under a consent decree with enhanced FDA oversight.

Event-causation diagram of the February 2022 Abbott Sturgis Cronobacter recall and its aftermath, detection, Sturgis plant shutdown, national shortage, Operation Fly Formula, plant reopening, and the structural market changes that followed — Timeline: Feb 2022 Cronobacter detection and 4 illnesses → plant shutdown Feb 17 → national shortage peaks May 2022 → Operation Fly Formula airlifts from Europe → Sturgis reopens July 2022 → market restructuring with Bobbie, ByHeart, European imports gaining share → FDA reform legislation. Event reshaped US infant formula market.

The timeline

Pre-recall (September 2021: February 2022)

September 2021: first reported Cronobacter sakazakii infection in an infant fed Similac from the Sturgis facility
October 2021: FDA received a whistleblower complaint from a former Abbott employee alleging production safety violations, falsified records, and leadership retaliation
December 2021: a second infant illness reported
January 2022: FDA began on-site inspection of the Sturgis plant
February 15, 2022: FDA Form 483 observations issued citing multiple GMP violations

Recall (February 17, 2022)

Abbott announced a voluntary recall of:

Similac (all Sturgis-produced powder variants)
Alimentum (extensively hydrolyzed specialty formula)
EleCare (amino acid-based formula for severe allergy)

Product lot numbers included the first two digits "22" through "37" manufactured at Sturgis.

Shortage cascade (March: June 2022)

March 2022: retailers began rationing formula; out-of-stock rates climbed weekly
April 2022: national out-of-stock rates approached 40%
May 2022: at peak shortage, some states reported 50%+ out-of-stock rates in the formula category
May 18, 2022: President Biden invoked the Defense Production Act for infant formula
May 22, 2022: Operation Fly Formula launched, coordinating military aircraft to import EU-manufactured formula
June 2022: FDA announced enforcement discretion pathway allowing temporary import of foreign-manufactured infant formula from Nestlé (Australia), Kendamil (UK), Bubs (Australia), Bebelac (various), and others

May 16, 2022: Abbott signed a consent decree with the FDA and DOJ committing to enhanced sanitation, microbiological testing, training, and third-party audit requirements
July 1, 2022: Sturgis plant reopened production of EleCare (the specialty amino-acid formula)
Later July 2022: Similac production resumed incrementally

Post-recall (2023: present)

Congressional hearings in 2022 revealed significant regulatory oversight gaps
FDA reorganization announced, the Office of Critical Foods created in 2023 to centralize infant formula oversight
FDA Enforcement Discretion for several European brands (including Kendamil) continues or has been codified in various forms
Consumer trust: survey data show sustained preference shifts toward non-Abbott brands and toward European imports

What the FDA found at the Sturgis plant

The FDA Form 483 (inspection observations) cited multiple failures:

Microbial contamination

Cronobacter sakazakii found in multiple plant environmental samples, including on production equipment
Positive samples documented at multiple time points pre-recall
Testing frequency and protocol deviations identified

Sanitation and facility control

Failure to maintain equipment in sanitary condition
Water and condensation management issues
Cracks and crevices in production surfaces allowing microbial harborage
Inadequate separation between different production lines

Documentation and quality system failures

Incomplete record-keeping of environmental monitoring
Failure to thoroughly investigate previous positive samples
Inadequate corrective action when contamination events were identified
Whistleblower complaint alleged falsified records (investigated independently by House Oversight Committee)

Training and management

Documented gaps in employee training on GMP requirements
Supervisory oversight gaps

What Abbott changed post-recall

Under the consent decree, Abbott committed to:

Enhanced environmental monitoring with public reporting to FDA
Third-party audit requirements
Expanded microbiological testing of incoming ingredients and finished product
Increased training documentation
Structural and equipment upgrades at Sturgis
Leadership and oversight changes at the facility

The shortage: what parents actually experienced

During April–June 2022, parents encountered a cascade of supply failures — specialty formula disappearing from every US retailer, standard formula stockouts rotating by region, and WIC families specifically hit by contract-brand shortages. If a future shortage of similar scale recurs, the formula shortage navigator documents the decision tree parents should run through.

Specialty formula crisis

EleCare (amino-acid formula) and Alimentum (extensively hydrolyzed) are medically necessary for infants with severe CMPA or other conditions who cannot tolerate standard formula. With Sturgis, the only US producer of EleCare, shut down, families with medically-complex infants had almost no domestic alternatives.

Operation Fly Formula specifically targeted imports to address this subgroup's needs first. Nestlé Alfamino (from Europe) and Bubs/Bebelac were airlifted in specifically to fill the specialty gap.

Standard formula rationing

Retailers capped purchases (typically 2-3 cans per customer)
Online prices spiked; price gouging was documented but inconsistently prosecuted
Social media networks emerged for parents to coordinate supply sourcing
Cross-state driving to find specific brands became common

Pediatric advice shifts

Pediatricians began explicitly approving alternate brands they previously wouldn't have recommended
Switching across brand categories (milk-based → soy-based, or standard → gentle) became common based on availability rather than clinical indication
The AAP issued interim guidance on switching formulas during the shortage

WIC program response

Some state WIC programs relaxed contract-brand requirements
Federal waivers allowed cross-brand WIC redemption in affected states

Why Cronobacter is specifically dangerous in infant formula

Cronobacter sakazakii is a gram-negative bacterium that causes rare but devastating infections in infants under 2 months:

Sepsis, systemic bloodstream infection
Meningitis, brain and spinal cord inflammation, with high mortality
Necrotizing enterocolitis, intestinal inflammation and damage

Infection rates among exposed infants are low, but case fatality rates are very high, approximately 30-40% in confirmed cases. Survivors often have significant neurological sequelae.

The bacterium is particularly concerning for powdered infant formula because:

Powder is not a sterile product, small bacterial loads can survive manufacturing
Infant formula is often reconstituted with water that may not kill bacteria (water below 70°C)
Young infants have immature immune systems especially vulnerable to bloodstream infections

For preparation practices that reduce Cronobacter risk, see how to prepare baby formula safely and storing baby formula.

Structural consequences of the recall

Bobbie, launched 2021, grew significantly during the shortage as a US-made organic alternative
Kendamil, received US enforcement discretion; now in limited US retail (Target)
ByHeart: US-made A2 launched 2022, grew during the aftermath
Reckitt/Mead Johnson (Enfamil parent), benefited from Abbott's shortfall

Abbott's pre-recall market share was approximately 40-45% of US infant formula; estimates put the post-recall equilibrium at 30-35%.

Regulatory changes

Office of Critical Foods established at FDA in 2023 to centralize infant formula and other critical food oversight
Enhanced inspection protocols at US infant formula facilities
Permanent enforcement discretion pathway discussion for selected foreign brands
"Resilience" framework. FDA and USDA began developing contingency plans for future supply disruptions

Consumer behavior

Survey data post-2022 show:

Increased parental research before formula selection
Growing interest in European imports (HiPP, Holle, Kendamil, Lebenswert)
Greater willingness to compare brands
Heightened attention to plant of origin on labels

What this means for parents today

The Abbott plant is operating under enhanced oversight

Sturgis-produced Similac, EleCare, and Alimentum are back on US shelves under consent-decree conditions including third-party audit and expanded testing. Whether this makes Sturgis-produced Abbott formula safer than pre-recall or simply at industry baseline is a reasonable open question.

European brand availability has improved permanently

The FDA enforcement discretion pathway established during the crisis has persisted in various forms. Kendamil, Bubs, and others have durable US presence. Organic's Best Shop and similar importers operate more openly than before 2022.

For the current legality framework, see is European formula FDA-approved? and buying European formula in the USA.

Specialty formula supply remains fragile

EleCare and Alimentum remain produced primarily at Sturgis. Any future disruption at the plant would again affect medically-complex infants most severely. Domestic manufacturing diversity for specialty formulas remains limited.

Recall tracking matters

Parents reasonably want to know:

Whether their current brand has had recalls
What the recalls were for (minor labeling vs. microbial contamination vs. death)
What the brand's response was

This is why the Atlas records recall_history[] for each SKU and tracks reformulations at the brand level. See Bobbie and ByHeart for brand-level records with recall transparency, and the historical timeline at formula recall history USA.

Editorial notes from María

The 2022 Abbott recall is the single event that most shaped how US parents think about infant formula today. I started researching this space heavily in its aftermath, the fact that the market was so concentrated, that one plant's failure cascaded into a national crisis, and that there was essentially no mainstream consumer resource documenting brands, plants, and alternatives was part of what motivated this Atlas.

Four years later, Abbott is back on shelves and selling well. Parents have largely returned to prior brand preferences. But the infrastructure that responded to the crisis: European brand availability, greater comparing, more informed parents, has durably changed the landscape. This article is meant as a factual reference for parents who want to understand that history.

FAQ

What caused the 2022 Abbott formula recall?

FDA inspection of the Sturgis, Michigan plant found Cronobacter sakazakii in the facility environment and multiple GMP violations including sanitation failures, documentation gaps, and environmental control issues. Four infant illnesses and at least two deaths linked to Cronobacter and Salmonella from the facility triggered the voluntary recall on February 17, 2022.

How long was the US infant formula shortage?

The most acute shortage phase ran from March 2022 through July 2022, with peak out-of-stock rates of 40-50% in April-May. Supply began recovering when the Sturgis plant partially reopened in July 2022 and European imports via Operation Fly Formula filled gaps. Full market recovery took approximately 9-12 months.

Is Similac safe now after the recall?

Sturgis-produced Similac, EleCare, and Alimentum are back on US shelves under a consent decree requiring enhanced sanitation, testing, and third-party audit oversight. Whether this brings Sturgis-produced product to a higher safety standard than pre-recall or simply to industry baseline is a reasonable question. Most pediatricians and parents are using the products normally at this point.

What is Cronobacter and why is it dangerous?

Cronobacter sakazakii is a gram-negative bacterium that causes rare but devastating infections in young infants, sepsis, meningitis, and necrotizing enterocolitis. Case fatality rates in confirmed infections are approximately 30-40%. Powdered infant formula is a known risk vehicle because powder is not sterile and Cronobacter can survive low-temperature reconstitution.

Did the FDA know about Cronobacter at Sturgis before the recall?

Congressional hearings revealed that a whistleblower complaint alleging production safety violations was filed with the FDA in October 2021, approximately four months before the February 2022 recall. The timeline of FDA response and investigation became a significant regulatory criticism. The Office of Critical Foods was created partly in response to these oversight gaps.

How did the recall change what formulas are available in the US?

Enforcement discretion pathways allowed temporary and in some cases durable US presence for European and Australian brands (Kendamil, Bubs, select Nestlé products). Bobbie, ByHeart, and other newer US entrants grew market share. Imports through retailers like Organic's Best Shop became more visible and organized. The US market is structurally less Abbott-concentrated than pre-2022.

Can this happen again?

Structurally, yes. The US infant formula market remains concentrated: Abbott, Reckitt/Mead Johnson, Perrigo, and Nestlé produce most supply. Specialty formulas (amino-acid, extensively hydrolyzed) are particularly concentrated. A disruption at another major plant could trigger a similar cascade. FDA's Office of Critical Foods was created partly to address contingency planning, but the structural concentration has not fundamentally changed.

Primary sources

FDA: Investigation: Cronobacter Infections Linked to Powdered Infant Formula, February 2022. fda.gov
FDA Form 483: Observations from Abbott Nutrition Sturgis, MI facility. fda.gov
US House Oversight Committee: Report on the Infant Formula Crisis. oversight.house.gov
FDA Consent Decree: Abbott Nutrition, May 2022.
CDC: Cronobacter Investigation and Outbreak Summary 2022. cdc.gov
White House Briefing Room: Defense Production Act Invocation and Operation Fly Formula, May 2022.

Similac brand hub (the brand family at the center of the recall: Pro-Advance, Alimentum, EleCare)
Product-level comparison expressing Abbott's recall legacy, Bobbie Original vs Similac Organic (independent challenger brand vs big-brand with parent Abbott 2022 recall context)
US formula recall history cross-brand
Formula shortage preparedness (what 2022 taught about stock buffers)
Formula shortage navigator

This site provides research and comparisons, not medical advice. Consult your pediatrician before changing your baby's formula.